GSK
GSK plc$53.04
LiveJun 12, 2026
Market cap
$106.31B
52w range
35.45 – 61.70
P / E
—
EPS
—
Volume
3.81M
Revenue · FY
—
Explain this page
Arphra AIPlain-English read on GSK plc’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $52.45 (-1.11%)
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.34% | +3.35% | +6.78% | -0.66% | +7.72% | +8.16% | +31.00% | +50.38% | +30.74% | +32.47% | +7982.29% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$53.50
Bid
$52.00
500 sh
Ask
$53.60
1,400 sh
Spread
$1.600
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Sector & industry today
LiveSectors
- Utilities+2.58%
- Energy+1.31%
- Basic Materials+0.81%
- Consumer Defensive+0.72%
- Technology+0.67%
- Real Estate+0.47%
- Financial Services+0.33%
- Industrials+0.06%
- Consumer Cyclical-0.34%
- Communication Services-0.77%
- Healthcare-1.62%
Top industries (issuer's industry highlighted)
- Drug Manufacturers - General-2.21%
- Broadcasting-4.06%
- Coal+3.67%
- Renewable Utilities+3.61%
- Silver+3.21%
- Computer Hardware+2.54%
- Medical - Equipment & Services-2.31%
- Oil & Gas Energy+2.30%
- Auto - Dealerships-2.28%
- Copper+2.24%
- Medical - Healthcare Information Services-2.20%
- Oil & Gas Exploration & Production+2.18%
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- GSK's Momelotinib Gets Orphan Tag for Rare Hemato-Inflammatory Disorderzacks.com·Jun 12, 2026
- Is GSK PLC (GSK) Overvalued After 3.3% Rally? GF Value Says Overvaluedgurufocus.com·Jun 11, 2026
- Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billionmarketbeat.com·Jun 11, 2026
- Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent dealreuters.com·Jun 11, 2026
- GSK plc (GSK) M&A Call Transcriptseekingalpha.com·Jun 10, 2026
- GSK's Nuvalent deal tackles HIV cliff to win cautious backing from analystsproactiveinvestors.co.uk·Jun 10, 2026
- After shedding its cancer business just over a decade ago, GSK's new CEO is building back with a $10.6 billion dealwsj.com·Jun 09, 2026
- GSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyoutzacks.com·Jun 09, 2026
Recent analyst activity
DB- Jun 09, 2026GradeOutperform → OutperformRBC Capital: 'On balance we think readthroughs from the GSK acquisition of NUVB's key competitor are positive'RBC Capital
Peers
No peer list available for GSK.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|